Back to top
more

Urovant Sciences Ltd. (UROV)

(Delayed Data from NSDQ)

$8.04 USD

8.04
4,998

+0.04 (0.50%)

Updated May 3, 2019 04:13 PM ET

After-Market: $8.04 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[UROV]

Reports for Purchase

Showing records 1 - 16 ( 16 total )

Industry: Medical - Biomedical and Genetics

Record: 1

12/28/2020

Company Report

Pages: 4

Gemtesa Approval on Schedule; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

11/16/2020

Company Report

Pages: 4

Sumitovant Acquisition Deal Looks Priced in; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

11/13/2020

Company Report

Pages: 4

Sumitovant to Acquire Remaining Urovant Shares; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

08/19/2020

Company Report

Pages: 5

Awaiting Vibegron Approval in December; F1Q20 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

06/19/2020

Company Report

Pages: 5

F2019 Financial Results Reported; Modulating PT to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

06/09/2020

Company Report

Pages: 5

Commercial Team Takes Shape; Vibegron Japan Sales Promising; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

03/10/2020

Company Report

Pages: 5

Vibegron Filing Acceptance; Anticipating Smooth Path to Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

02/05/2020

Company Report

Pages: 5

Promising URO-902 Phase 1 Data Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

12/31/2019

Company Report

Pages: 5

Sumitomo Dainippon Loan Agreement Finalized; Vibegron Filing Submitted; Raising PT to $33

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

10/21/2019

Company Report

Pages: 4

Still Undervalued Approaching Vibegron Submission; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

09/09/2019

Company Report

Pages: 5

Alliance Between Dainippon Sumitomo Pharma and Roivant Sciences Bodes Well for Urovant; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

08/14/2019

Company Report

Pages: 5

F1Q19 Financial Results Reported; Vibegron Progressing Towards Regulatory Submission; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

06/24/2019

Company Report

Pages: 5

Market Research Provides Favorable Vibegron Outlook; Fiscal 2019 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

06/10/2019

Company Report

Pages: 5

Vibegron Potential Remains Underrated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

03/22/2019

Company Report

Pages: 5

EMPOWUR Study Achieves Significance on Multiple Endpoints; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

03/11/2019

Company Report

Pages: 31

Upending the Status Quo in Urology; Initiating at Buy and $28 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 75.00

Research Provided by a Third Party
// eof